Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7650602 | 0.95 | ADAM17 (0.62) | ADAM17MMP13 | |
| SCHEMBL6741903 | 0.90 | ADAM17 (0.49) | ADAM17 | |
| Trifluoroacetic Acid SCHEMBL6736529 | 0.88 | ADAM17 (0.62) | ADAM17 | |
| Trifluoroacetic Acid SCHEMBL6736943 | 0.85 | ADAM17 (0.57) | ADAM17MMP13 | |
| SCHEMBL6741074 | 0.83 | ADAM17 (0.68) | ADAM17 | |
| Trifluoroacetic Acid SCHEMBL6736923 | 0.83 | ADAM17 (0.57) | ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL7656192 | 0.83 | ADAM17 (0.55) | ADAM17 | |
| Trifluoroacetic Acid SCHEMBL6737321 | 0.81 | ADAM17 (0.57) | ADAM17 | |
| Trifluoroacetic Acid SCHEMBL6744361 | 0.81 | ADAM17 (0.62) | ADAM17 | |
| Trifluoroacetic Acid SCHEMBL6742567 | 0.81 | ADAM17 (0.62) | ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689771-B2 | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | DUAN JINGWU (US) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | TNF, MMP1, ADAMTS1 | ADAM17 11/4885MMP13 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.